Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Abrysvo
Pharma
GSK's Arexvy shows promise in younger adults
Results from two trials showed that GSK’s RSV vaccine Arexvy has potential in younger adults with certain risk factors.
Kevin Dunleavy
Oct 24, 2024 10:32am
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
Oct 23, 2024 11:11am
Pfizer's RSV vaccine benefits immunocompromised adults
Aug 12, 2024 10:20am
With new CDC guidelines, RSV market value falls sharply: report
Jul 29, 2024 12:04pm
UK selects Pfizer over GSK to supply RSV vaccines for 2 years
Jun 24, 2024 11:19am
GSK's Arexvy has expanded its label into adults ages 50-59
Jun 7, 2024 6:45pm
